Risk Factors and Changes of Peripheral NK and T Cells in Pulmonary Interstitial Fibrosis of Patients with Rheumatoid Arthritis

Table 1

Clinical characteristics in RA-ILD and RA.

	RA-ILD (n = 100)	RA (n = 100)
Male/female	43/57	25/75	0.011
Age (year, mean ± SD)	63.89 ± 8.99	53.26 ± 13.24	0.000
Disease duration (year, mean ± SD)	9.87 ± 10.23	9.05 ± 8.28	0.941
RF (IU/ml, mean ± SD)	391.05 ± 413.34	221.02 ± 321.53	0.000
ACPA (IU/ml, mean ± SD)	828.77 ± 584.23	471.57 ± 549.60	0.000
ESR (mm/h, mean ± SD)	67.84 ± 34.42	62.88 ± 38.53	0.236
CRP (mg/L, mean ± SD)	32.72 ± 36.74	33.36 ± 37.49	0.846
IgG (g/L, mean ± SD)	14.68 ± 6.14	14.18 ± 3.85	0.953
IgA (g/L, mean ± SD)	3.32 ± 1.31	3.08 ± 1.34	0.156
IgM (g/L, mean ± SD)	1.52 ± 0.89	1.43 ± 0.77	0.424
Treatment (users/nonusers)	87/13	91/9	0.499
NSAIDs (users/nonusers)	58/42	69/31	0.142
GCs (users/nonusers)	18/82	16/84	0.851
DMARDs (users/nonusers)	11/89	22/78	0.056
GCs + DMARDs (users/nonusers)	38/62	25/75	0.067
Biological agents (users/nonusers)	4/96	11/89	0.105

ESR: erythrocyte sedimentation rate, RF: rheumatoid factor, ACPA: antibodies to cyclic citrullinated peptides, CRP: C-reactive protein, NSAIDs: nonsteroidal anti-inflammatory drugs, GCs: glucocorticoids, and DMARDs: disease-modifying antirheumatic drugs.